Namilumab

Drug Profile

Namilumab

Alternative Names: AMG 203; Amg203; MT-203

Latest Information Update: 16 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Micromet Inc
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 10 May 2017 Discontinued - Phase-II for Plaque psoriasis (In the elderly, In adults) in Latvia, Poland, Germany, Denmark, and Canada (SC) because a phase II trial did not meet its primary endpoint (Takeda FY2016 Q4 results, May 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Takeda completes the TELLUS trial in Rheumatoid arthritis (Combination therapy, In adults, In elderly) in United Kingdom, Czech Republic, Estonia, Spain (EudraCT2014-002945-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top